NOMD bets on fish innovation and brand revamps to counter falling revenue, volume and organic sales trends.

NOMD bets on fish innovation and brand revamps to counter falling revenue, volume and organic sales trends.

Pfizer's broader portfolio and higher dividend yield give it an edge over Bristol Myers in the oncology showdown.

Pfizer's broader portfolio and higher dividend yield give it an edge over Bristol Myers in the oncology showdown.

AGNC's active portfolio shifts and strong hedge stance aim to boost long-term growth despite near-term earnings pressure.

LLY's blockbuster obesity drugs fuel rapid growth but ABBV's valuation and pipeline may offer safer short-term upside.

We're halfway through 2025 and so much has happened that has created so much uncertainty that the Calgary Real Estate Board (CREB) is now downgrading...

We're halfway through 2025 and so much has happened that has created so much uncertainty that the Calgary Real Estate Board (CREB) is now downgrading...

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

CLX bets on global growth as it expands in Latin America and Asia, aiming to offset slowing U.S. sales with long-term international gains.